Obinutuzumab Plus Chemotherapy As First Line Treatment in Patients with Follicular Lymphoma: Experience from a Community Hospital

被引：1
|
作者：
de Una, Soraya Lorente [1 ]
Gutierrez, Javier [1 ]
Gonzalez, Matilde [1 ]
Kumar, Anjana [1 ]
Morales, Elena [1 ]
Herrada, Juan [1 ]
机构：
[1] Hosp Vithas Xanit Int, Hematol Dept, Benalmadena, Malaga, Spain
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-167896
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：12001 / 12001
页数：1
相关论文
共 50 条
  • [21] Chemotherapy-Free Combination of Obinutuzumab and Ibrutinib in First LINE Treatment of Follicular Lymphoma. the Alternative Study By the German Low Grade Lymphoma Study Group (GLSG)
    Schmidt, Christian
    Zoellner, Anna-Katharina
    Jurinovic, Vindi
    Soekler, Martin
    Forstpointner, Roswitha
    Haubner, Sascha
    Buske, Christian
    Viardot, Andreas
    Keller, Ulrich
    Pott, Christiane
    Graeven, Ullrich
    Marks, Reinhard
    Haenel, Mathias
    Liersch, Ruediger
    Duerig, Jan
    Hoster, Eva
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2018, 132
  • [22] Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study
    Flowers, Christopher
    Zinzani, Pier Luigi
    Mayer, Jiri
    Bijou, Fontanet
    de Oliveira, Ana C.
    Song, Yuqin
    Zhang, Qingyuan
    Merli, Michele
    Bouabdallah, Krimo
    Ganly, Peter S.
    Zhang, Huilai
    Yuen, Sam
    Kingsley, Ed
    Assouline, Sarit E.
    Auer, Rebecca
    Kim, Pil
    Greenbaum, Adam
    Huang, Sha
    Delarue, Richard
    Trotman, Judith
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] RITUXIMAB-BENDAMUSTINE AS FIRST LINE OF TREATMENT IN PATIENTS WITH FOLLICULAR LYMPHOMA. EXPERIENCE OF ONE CENTER
    Melian Haridian, De la Nuez
    Henriquez Hugo, Luzardo
    Cabrera Alexia, Suarez
    Gonzalez Paula, Fernandez-Caldas
    Cruz Naylen, Cruz
    Borrego Asuncion, Borrero
    Juan Francisco, Lopez Rodriguez
    Curbelo Alejandro, Morales
    De La Cruz Marcos, Cabezas
    Maria Teresa, Gomez Casares
    HAEMATOLOGICA, 2021, 106 (10) : 296 - 297
  • [24] FIRST LINE TREATMENT WITH BENDAMUSTINE-RITUXIMAB IN PATIENTS WITH FOLLICULAR LYMPHOMA
    Buenasmananas Cervantes, D.
    Calle Primo, C.
    Nebro Luque, M. dM
    Hernandez Ruiz, B.
    HAEMATOLOGICA, 2015, 100 : 266 - 266
  • [25] Comparison of efficacy and safety with obinutuzumab plus chemotherapy versus rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Updated results from the phase III Gallium Study.
    Townsend, William
    Buske, Christian
    Cartron, Guillaume
    Cunningham, David
    Dyer, Martin J. S.
    Gribben, John G.
    Zhang, Zilu
    Rufibach, Kaspar
    Nielsen, Tina
    Herold, Michael
    Hiddemann, Wolfgang
    Marcus, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] EVALUATING THE COST-EFFECTIVENESS OF THE ADDITION OF RITUXIMAB TO CHEMOTHERAPY IN THE FIRST LINE TREATMENT OF FOLLICULAR LYMPHOMA PATIENTS IN THE UK
    Rafia, R.
    Papaioannou, D.
    Stevenson, M.
    Rathbone, J.
    Woods, H. B.
    VALUE IN HEALTH, 2011, 14 (07) : A445 - A445
  • [27] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong, Xiaonan
    Song, Yuqin
    Shi, Yuankai
    Zhang, Qingyuan
    Guo, Wei
    Wu, Gang
    Li, Junmin
    Feng, Jifeng
    Kinkolykh, Anastasiia
    Knapp, Andrea
    Lin, Tongyu
    CHINESE MEDICAL JOURNAL, 2022, 135 (04) : 433 - 440
  • [28] Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase III GALLIUM study
    Hong Xiaonan
    Song Yuqin
    Shi Yuankai
    Zhang Qingyuan
    Guo Wei
    Wu Gang
    Li Junmin
    Feng Jifeng
    Kinkolykh Anastasiia
    Knapp Andrea
    Lin Tongyu
    中华医学杂志英文版, 2022, 135 (04) : 433 - 440
  • [29] Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy
    Jamois, Candice
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Buchheit, Vincent
    Sahin, Denis
    Cartron, Guillaume
    Marcus, Robert
    Hiddemann, Wolfgang
    Seymour, John F.
    Strefford, Jonathan C.
    Hargreaves, Chantal E.
    Meneses-Lorente, Georgina
    Frey, Nicolas
    Fingerle-Rowson, Guenter
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1495 - 1506
  • [30] Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG)
    Paszkiewicz-Kozik, Ewa
    Hus, Iwona
    Palka, Monika
    Debowska, Malgorzata
    Konska, Agnieszka
    Kotarska, Martyna
    Tyczynska, Agata
    Joks, Monika
    Twardosz, Maja
    Giza, Agnieszka
    Wasik-Szczepanek, Ewa
    Kalicinska, Elzbieta
    Wisniewska, Anna
    Morawska, Marta
    Romejko-Jarosinska, Joanna
    Lewicka, Barbara
    Targonski, Lukasz
    Osowiecki, Michal
    Poplawska, Lidia
    Szymanski, Marcin
    Kruczkowska-Taranowicz, Kamila
    Drozd-Sokolowska, Joanna
    Swoboda, Ryszard
    Domanska-Czyz, Katarzyna
    Ostrowska, Beata
    Swierkowska, Monika
    Dabrowska-Iwanicka, Anna Paulina
    Druzd-Sitek, Agnieszka
    Konecki, Robert
    Borawska, Anna
    Dlugosz-Danecka, Monika
    Lech-Maranda, Ewa
    Walewski, Jan
    BLOOD, 2021, 138
12345